Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib, its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research, AACR, Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9. Data from bemaciclib, Lilly's CDK4/6 inhibitor LY2835219 as a potential treatment for metastatic breast cancer, has been accepted as a late-breaking presentation that will be included at AACR's Clinical Trials Symposium and will be featured in an official AACR-sponsored press conference. "The CDK4/6 pathway is one of the most commonly implicated pathways in all cancers, making it an important area for research," said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. "The single-agent activity we've observed for bemaciclib is encouraging in this setting and we believe the data support the need for further development in metastatic breast cancer."